Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 6:43 pm Purchase |
2024-12-31 | 13G | Unicycive Therapeutics, Inc. UNCY |
RA Capital Management, L.P. | 11,520,120 9.900% |
1,047,745 (+10.00%) |
Filing History |
| 2025-02-14 4:39 pm Purchase |
2024-12-31 | 13G | Unicycive Therapeutics, Inc. UNCY |
GREAT POINT PARTNERS LLC | 11,473,166 9.990% |
1,950,734 (+20.49%) |
Filing History |
| 2025-02-06 3:08 pm Unchanged |
2024-12-31 | 13G | Unicycive Therapeutics, Inc. UNCY |
Walleye Capital LLC | 5,000,000 4.820% |
0 (Unchanged) |
Filing History |
| 2024-12-20 4:32 pm Purchase |
2024-12-19 | 13G | Unicycive Therapeutics, Inc. UNCY |
Nantahala Capital Management, LLC | 10,879,142 9.990% |
719,793 (+7.09%) |
Filing History |
| 2024-12-20 4:31 pm Sale |
2024-12-19 | 13G | Unicycive Therapeutics, Inc. UNCY |
Nantahala Capital Partners Limited Partnership | 3,009,021 2.760% |
-4,878,815 (-61.85%) |
Filing History |
| 2024-11-14 7:13 pm Purchase |
2024-09-30 | 13G | Unicycive Therapeutics, Inc. UNCY |
Logos Global Management LP | 5,078,927 4.900% |
5,078,927 (New Position) |
Filing History |
| 2024-11-14 7:01 pm Purchase |
2024-10-09 | 13G | Unicycive Therapeutics, Inc. UNCY |
Vivo Opportunity Fund Holdings, L.P. | 60,961,729 9.990% |
1,000,000 (+1.67%) |
Filing History |
| 2024-11-14 5:46 pm Purchase |
2024-09-30 | 13G | Unicycive Therapeutics, Inc. UNCY |
RA Capital Management, L.P. | 10,472,375 9.990% |
7,000,269 (+201.61%) |
Filing History |
| 2024-11-14 5:05 pm Purchase |
2024-09-30 | 13G | Unicycive Therapeutics, Inc. UNCY |
GREAT POINT PARTNERS LLC | 9,522,432 9.990% |
963,432 (+11.26%) |
Filing History |
| 2024-11-14 4:53 pm Purchase |
2024-09-30 | 13G | Unicycive Therapeutics, Inc. UNCY |
Nantahala Capital Management, LLC | 10,159,349 9.990% |
6,683,636 (+192.30%) |
Filing History |
| 2024-11-14 4:53 pm Purchase |
2024-09-30 | 13G | Unicycive Therapeutics, Inc. UNCY |
Nantahala Capital Partners Limited Partnership | 7,887,836 7.760% |
5,766,083 (+271.76%) |
Filing History |
| 2024-11-14 4:29 pm Purchase |
2024-09-30 | 13G | Unicycive Therapeutics, Inc. UNCY |
BIOTECHNOLOGY VALUE FUND L P | 10,471,230 9.990% |
7,001,005 (+201.74%) |
Filing History |
| 2024-11-13 4:52 pm Purchase |
2024-09-30 | 13G | Unicycive Therapeutics, Inc. UNCY |
Walleye Capital LLC | 5,000,000 5.300% |
5,000,000 (New Position) |
Filing History |
| 2024-10-11 4:02 pm Purchase |
2024-09-30 | 13G | Unicycive Therapeutics, Inc. UNCY |
Octagon Capital Advisors LP | 8,559,000 9.100% |
8,559,000 (New Position) |
Filing History |
| 2024-07-18 4:10 pm Purchase |
2024-07-16 | 13G | Unicycive Therapeutics, Inc. UNCY |
GREAT POINT PARTNERS LLC | 8,559,000 9.990% |
8,559,000 (New Position) |
Filing History |
| 2024-02-14 6:41 pm Purchase |
2023-12-31 | 13G | Unicycive Therapeutics, Inc. UNCY |
RA Capital Management, L.P. | 3,472,106 9.990% |
1,417 (+0.04%) |
Filing History |
| 2024-02-14 4:51 pm Purchase |
2023-12-31 | 13G | Unicycive Therapeutics, Inc. UNCY |
Nantahala Capital Management, LLC | 3,475,713 9.900% |
2,268,297 (+187.86%) |
Filing History |
| 2024-02-14 3:18 pm Unchanged |
2023-12-31 | 13G | Unicycive Therapeutics, Inc. UNCY |
Armistice Capital, LLC | 976,000 2.730% |
0 (Unchanged) |
Filing History |
| 2024-02-02 8:32 pm Purchase |
2023-09-29 | 13G | Unicycive Therapeutics, Inc. UNCY |
Nantahala Capital Partners Limited Partnership | 2,121,753 6.100% |
2,121,753 (New Position) |
Filing History |
| 2024-01-22 4:27 pm Purchase |
2023-06-26 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Logos Global Management LP | 3,469,927 9.900% |
3,469,927 (New Position) |
Filing History |